Income Statement

The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

Regeneron Pharmaceuticals Inc., consolidated income statement

US$ in thousands

12 months ended:	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net product sales	7,629,200)	7,078,000)	6,893,700)	12,117,200)	5,567,600)
Collaboration revenue	6,057,800)	5,503,100)	4,914,100)	3,673,300)	2,372,500)
Other revenue	515,000)	536,100)	365,100)	281,200)	557,000)
Revenues	14,202,000)	13,117,200)	12,172,900)	16,071,700)	8,497,100)
Cost of goods sold	(1,087,300)	(932,100)	(800,000)	(1,773,100)	(491,900)
Cost of collaboration and contract manufacturing	(883,200)	(883,700)	(760,400)	(664,400)	(628,000)
Cost of revenues	(1,970,500)	(1,815,800)	(1,560,400)	(2,437,500)	(1,119,900)
Gross profit	12,231,500)	11,301,400)	10,612,500)	13,634,200)	7,377,200)
Research and development	(5,132,000)	(4,439,000)	(3,592,500)	(2,860,100)	(2,647,000)
Acquired in-process research and development	(101,000)	(186,100)	(255,100)	(48,000)	(88,000)
Selling, general, and administrative	(2,954,400)	(2,631,300)	(2,115,900)	(1,824,900)	(1,346,000)
Other operating income (expense), net	(53,400)	2,100)	89,900)	45,600)	280,400)
Income from operations	3,990,700)	4,047,100)	4,738,900)	8,946,800)	3,576,600)
Other income (expense), net	844,400)	225,200)	179,300)	436,300)	290,700)
Interest expense	(55,200)	(73,000)	(59,400)	(57,300)	(56,900)
Other income (expense)	789,200)	152,200)	119,900)	379,000)	233,800)
Income before income taxes	4,779,900)	4,199,300)	4,858,800)	9,325,800)	3,810,400)
Income tax expense	(367,300)	(245,700)	(520,400)	(1,250,500)	(297,200)
Net income	4,412,600)	3,953,600)	4,338,400)	8,075,300)	3,513,200)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Download chart

Income statement item	Description	The company
Revenues	Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.	Regeneron Pharmaceuticals Inc. revenues increased from 2022 to 2023 and from 2023 to 2024.
Income from operations	The net result for the period of deducting operating expenses from operating revenues.	Regeneron Pharmaceuticals Inc. income from operations decreased from 2022 to 2023 and from 2023 to 2024.
Income before income taxes	Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.	Regeneron Pharmaceuticals Inc. income before income taxes decreased from 2022 to 2023 but then increased from 2023 to 2024 not reaching 2022 level.
Net income	The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.	Regeneron Pharmaceuticals Inc. net income decreased from 2022 to 2023 but then increased from 2023 to 2024 exceeding 2022 level.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Income Statement